Nephros

Nephros develops and sells high-performance water purification filters, primarily serving medical markets. Its ultrafilters are used in hospitals and dialysis centers to remove biological contaminants, bacteria, viruses, and endotoxins from water and bicarbonate concentrate. Founded in 1997, Nephros is headquartered in South Orange, New Jersey.

Judy Krandel

CFO

2 past transactions

GenArraytion

Acquisition in 2021
GenArraytion Inc. is a veteran-owned small business based in Rockville, Maryland, specializing in molecular genotyping technologies for medical diagnostics. The company provides a range of products and services that focus on tick- and mosquito-borne diseases, epidemiology, source tracking, food and water testing, biodefense, and environmental monitoring. GenArraytion's offerings include MultiFLEX Bioassays and Sniper Sequencing genotyping services, which facilitate rapid and precise detection of infectious diseases, thereby enhancing response and treatment strategies. The company has developed advanced real-time multiplexed PCR assays, multiplexed bead-based assays, and custom microarrays, enabling simultaneous detection of multiple pathogens and antimicrobial characterization. GenArraytion is actively registered in the CCR database and holds ORCA certification.

Biocon

Acquisition in 2019
Biocon is a biopharmaceutical company focused on discovery, development, manufacturing and commercialization of biotechnology-based therapies. It operates across four segments: Biosimilars, Generics, Novel Biologics and Research Services. The company develops insulin products, monoclonal antibodies and other therapeutic proteins, including biosimilars, aimed at diabetes, oncology, immunology and autoimmune diseases. Through its subsidiary Syngene, Biocon provides integrated contract research and manufacturing services to the pharma industry. The group maintains substantial manufacturing capacity and serves markets in India and abroad, including the United States and Europe. A key subsidiary, Biocon Biologics, specializes in biosimilars and complex biologics, developing and commercializing a differentiated portfolio of biosimilars, novel biologics and APIs for global markets. The company emphasizes expanding patient access to affordable biologic therapies through its biosimilars and cost-effective development capabilities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.